Actively Recruiting
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
Led by Emory University · Updated on 2025-10-21
156
Participants Needed
2
Research Sites
289 weeks
Total Duration
On this page
Sponsors
E
Emory University
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).
CONDITIONS
Official Title
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with CKD (Stages III and IV), kidney transplant recipients with varying kidney function, or matched control participants without kidney disease
- Sedentary lifestyle, exercising less than 20 minutes twice per week
- Stable kidney function with no more than 1 cc/min/1.73 m2 decline in eGFR per month over the past 6 months
- Baseline serum bicarbonate between 22 and 24 mmol/L
- Presence of comorbid hypertension
You will not qualify if you...
- Severe CKD with eGFR less than 15 cc/min
- Metabolic alkalosis
- Current treatment with bicarbonate
- Ongoing drug or alcohol abuse
- Diabetic neuropathy or autonomic dysfunction
- Any serious disease affecting survival
- Anemia with hemoglobin less than 10 g/dL
- Clinical evidence of heart failure
- Volume overload or ejection fraction below 45%
- Symptomatic heart disease based on EKG, stress test, or history
- Treatment with central alpha-agonists (clonidine)
- Myocardial infarction or stroke within past six months
- Uncontrolled hypertension with blood pressure over 170/100 mm Hg
- Low blood pressure below 100/50 mm Hg
- Surgery within past 3 months
- Pregnancy or plans to become pregnant
- Inability to exercise on a stationary bicycle
- Contraindication to temporarily stopping alpha- and beta-blockers
- Peripheral arterial disease
- Class 3 obesity with BMI over 40
- Low or high potassium levels (less than 3.5 or greater than 5.0 meq/L)
- Current use of immunosuppressive medications
- Presence of arteriovenous fistula or graft
- Contraindications to MRI scanning including implanted devices or claustrophobia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Emory Clinic
Atlanta, Georgia, United States, 30322
Actively Recruiting
2
Atlanta VA Medical Center
Decatur, Georgia, United States, 30033
Actively Recruiting
Research Team
D
Dana DaCosta
CONTACT
J
Jeanie Park, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here